<DOC>
	<DOCNO>NCT00426933</DOCNO>
	<brief_summary>multicenter , randomize ( 1:1 ) , semi-single blind study compare safety efficacy HDSD daptomycin ( 10 mg/kg q24h 4 day ) comparator ( vancomycin +/- SSP 7-14 day ) patient cSSSI due Gram-positive bacteria . Patients randomize 1:1 basis receive either daptomycin 10 mg/kg i.v . q24h 4 day vancomycin 1 g. q12h 14 day .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study Daptomycin Complicated Skin Skin Structure Infections</brief_title>
	<detailed_description>multicenter , randomize ( 1:1 ) , semi-single blind study compare safety efficacy HDSD daptomycin ( 10 mg/kg q24h 4 day ) comparator ( vancomycin +/- SSP 7-14 day ) patient cSSSI due Gram-positive bacteria . Patients randomize 1:1 basis receive either daptomycin 10 mg/kg i.v . q24h 4 day vancomycin 1 g. q12h 14 day . The main criterion evaluation : - Efficacy - Safety - Microbiologic eradication</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>1 . Informed consent obtain 2 . Male female ≥18 year age 3 . If female childbearing potential , willing practice reliable birth control measure document negative pregnancy test 4 . Skin skin structure infection complicate nature require intravenous antibiotic treatment 5 . Grampositive infect pathogen 6 . Physician determination vancomycin would initial treatment choice 7 . At least three clinical sign symptom associate cSSSI : Pain ; Tenderness palpation ; Elevated Temperature ; Elevated White blood count ; Swelling and/or induration ; Erythema ( &gt; 1 cm beyond edge wound abscess ) ; Pus formation ; 8 . Creatinine clearance ≥50 mL/min . 1 . MSSA 2 . Known suspected bacteremia , osteomyelitis , endocarditis 3 . Primary study infection uncomplicated nature furuncle , simple abscess , cellulitis require i.v. , perirectal abscess , hidradenitis suppurativa , third degree burn infection minor infection ; 4 . Conditions require surgery ( ) constitute curative treatment infection ( e.g. , amputation ) ; 5 . Necrotizing infection concomitant gangrene ; 6 . Myositis without skin skin structure infection ; 7 . Hemodialysis peritoneal dialysis ; 8 . BMI ≥40 kg/m2 ; 9 . Previous antibiotic exceed 24 hour within 48 hour prior first dose study drug 10 . Patients admit rhabdomyolysis include drug overdose 11 . Neutropenic patient absolute neutrophil count ≤500 cells/mm3 12 . Known HIVinfected patient CD4 count ≤200 cells/ mm3 ; 13 . Baseline CPK value ≥2 X ULN ( upper limit normal ) ; 14 . Has receive investigational drug within 30 day study entry ; 15 . Known allergic intolerant study medication ; 16. unlikely comply study procedures 17 . Is expect receive HMG CoA Reductase Inhibitors enrollment End Treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>cSSSI</keyword>
	<keyword>MRSA</keyword>
</DOC>